EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Twelve-Month Real-World Outcomes of Tezepelumab in Severe Asthma: Clinical Remission, Biomarker Changes, and Trigger Burden—A SANI Multicenter Cohort

Stefania Nicola, Simone Negrini iD, Fulvia Ribolla, Giuseppe Guida iD, Rocco Francesco Rinaldo, Benedetta Bondi iD, Iuliana Badiu, Federica Corradi, Anna Quinternetto iD, Ilaria Vitali iD, Luca Lo Sardo iD, Benedetta Crida und 18 weitere

Journal of Personalized Medicine · 15.06.2026 · 16 (6) · 321

DOI: 10.3390/jpm16060321 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 15.06.2026. Verfasst von Stefania Nicola und 29 weiteren Autor:innen. Beteiligte Einrichtung: Immunology and Allergy Unit, Azienda Ospedaliera Ordine Mauriziano di Torino, 10128 Turin, Italy. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Tezepelumab targets thymic stromal lymphopoietin and has broad efficacy in severe asthma, yet real-world evidence on patient-reported trigger burden remains limited. We assessed 12-month outcomes after tezepelumab, focusing on clinical remission, biomarkers, and trigger profiling as complementary dimensions of response.

Methods

In this multicenter longitudinal real-world observational cohort based on routine clinical follow-up and Severe Asthma Network in Italy (SANI) registry data, 43 adults with severe asthma treated with tezepelumab at four Italian SANI reference centers were evaluated at baseline and, when available, after 1, 3, 6, and 12 months. Outcomes included exacerbations, lung function, type 2 biomarkers, the Asthma Control Test, SNOT-22, trigger categories, Asthma Trigger Inventory (ATI) scores, and SANI-defined clinical remission.

Results

Among 22 patients with 12-month follow-up data, mean annualized exacerbations decreased from 4.30 ± 2.77 to 0.36 ± 0.49 (p < 0.001), and 14/22 (63.6%) were exacerbation-free. Asthma control improved, whereas FEV1 remained stable. FeNO and blood eosinophils decreased at selected time points. The number of reported trigger categories was lower at 6 months (p < 0.001), and physical exertion, smoke, irritants, and infection-related ATI domains improved longitudinally. Complete clinical remission was achieved in 5/22 patients (22.7%).

Conclusions

Tezepelumab was associated with reduced exacerbations, improved asthma control, and lower patient-reported trigger burden. Structured trigger profiling may provide an exploratory patient-centered dimension for assessing treatment response in severe asthma.

Schlagwörter

Stichwörter der Autor:innen

Asthma Trigger InventorySANIbiologicsclinical remissionreal-world evidencesevere asthmatezepelumabthymic stromal lymphopoietintrigger burdentype 2 inflammation

Autor:innen und Institutionen

  • Immunology and Allergy Unit, Azienda Ospedaliera Ordine Mauriziano di Torino, 10128 Turin, Italy.
  • Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
  • Pneumology Unit, City of Health and Science, Molinette Hospital, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
  • Severe Asthma, Rare Lung Disease and Respiratory Pathophysiology Unit, San Luigi Gonzaga University Hospital, Orbassano, 10043 Turin, Italy.
  • Allergy and Respiratory Diseases, IRCCS Policlinico San Martino, University of Genoa, 16132 Genoa, Italy.
  • Struttura Semplice Dipartimentale Pediatric Allergology Unit, Regina Margherita Children Hospital, Azienda Ospedaliero-Universitaria (AOU) Città Della Salute e Della Scienza, 10126 Turin, Italy.

ORCID-Profile: Simone Negrini, Giuseppe Guida, Benedetta Bondi, Anna Quinternetto, Ilaria Vitali, Luca Lo Sardo, Enrico Heffler, Giorgio Walter Canonica, Francesco Blasi, Marzia Boem, Fabio Luigi Massimo Ricciardolo, Paolo Solidoro, Luisa Brussino

Zitieren

APA

Nicola, S., Negrini, S., Ribolla, F., Guida, G., Rinaldo, R. F., Bondi, B., Badiu, I., Corradi, F., Quinternetto, A., Vitali, I., Lo Sardo, L., Crida, B., Mhimid, L., Tocci, S. L., Teocchi, M., Milione, A., Marengo, M., Heffler, E., Canonica, G. W., …, & On Behalf Of The Sani Study Group (2026). Twelve-Month Real-World Outcomes of Tezepelumab in Severe Asthma: Clinical Remission, Biomarker Changes, and Trigger Burden—A SANI Multicenter Cohort. Journal of Personalized Medicine, 16(6), 321. https://doi.org/10.3390/jpm16060321

Vancouver

Nicola S, Negrini S, Ribolla F, Guida G, Rinaldo RF, Bondi B, et al. Twelve-Month Real-World Outcomes of Tezepelumab in Severe Asthma: Clinical Remission, Biomarker Changes, and Trigger Burden—A SANI Multicenter Cohort. Journal of Personalized Medicine. 2026;16(6):321. doi:10.3390/jpm16060321

BibTeX
@article{Nicola2026,
  author = {Nicola, Stefania and Negrini, Simone and Ribolla, Fulvia and Guida, Giuseppe and Rinaldo, Rocco Francesco and Bondi, Benedetta and Badiu, Iuliana and Corradi, Federica and Quinternetto, Anna and Vitali, Ilaria and Lo Sardo, Luca and Crida, Benedetta and Mhimid, Linda and Tocci, Sofia Luisa and Teocchi, Marcelo and Milione, Asia and Marengo, Marta and Heffler, Enrico and Canonica, Giorgio Walter and Blasi, Francesco and Paggiaro, Pierluigi and Boem, Marzia and Basiglio, Stefania and Alessi, Lucrezia and Braido, Fulvio and Ricciardolo, Fabio Luigi Massimo and Solidoro, Paolo and Bagnasco, Diego and Brussino, Luisa and On Behalf Of The Sani Study Group},
  title = {Twelve-Month Real-World Outcomes of Tezepelumab in Severe Asthma: Clinical Remission, Biomarker Changes, and Trigger Burden—A SANI Multicenter Cohort},
  journal = {Journal of Personalized Medicine},
  year = {2026},
  volume = {16},
  number = {6},
  pages = {321},
  doi = {10.3390/jpm16060321}
}
Kostenlos starten →